Felicity C Stark

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6007435/publications.pdf

Version: 2024-02-01

23 papers	455 citations	759055 12 h-index	713332 21 g-index
23 all docs	23 docs citations	23 times ranked	341 citing authors

#	Article	IF	Citations
1	Introduction to theÂImmune System. Methods in Molecular Biology, 2019, 2024, 1-24.	0.4	100
2	Introduction to the Immune System. Methods in Molecular Biology, 2013, 1061, 1-20.	0.4	42
3	Intracellular Bacterial Vectors That Induce CD8+ T Cells with Similar Cytolytic Abilities but Disparate Memory Phenotypes Provide Contrasting Tumor Protection. Cancer Research, 2009, 69, 4327-4334.	0.4	35
4	A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations. International Journal of Pharmaceutics, 2019, 561, 187-196.	2.6	34
5	Archaeosome Adjuvant Overcomes Tolerance to Tumor-Associated Melanoma Antigens Inducing Protective CD8⁺T Cell Responses. Clinical and Developmental Immunology, 2010, 2010, 1-13.	3.3	28
6	Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice. PLoS ONE, 2018, 13, e0208067.	1.1	28
7	Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization. Vaccine, 2019, 37, 7108-7116.	1.7	24
8	Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins. Vaccines, 2019, 7, 204.	2.1	23
9	Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants. Human Vaccines and Immunotherapeutics, 2018, 14, 1746-1759.	1.4	21
10	Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma. Biomedicines, 2019, 7, 91.	1.4	21
11	An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma. Vaccines, 2017, 5, 38.	2.1	14
12	Mechanistic insight into the induction of cellular immune responses by encapsulated and admixed archaeosome-based vaccine formulations. Human Vaccines and Immunotherapeutics, 2020, 16, 2183-2195.	1.4	14
13	Lack of Functional Selectin Ligand Interactions Compromises Long Term Tumor Protection by CD8+ T Cells. PLoS ONE, 2012, 7, e32211.	1.1	10
14	Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8+ T Cells that Protect Against Subcutaneous B16-OVA Melanoma. Vaccines, 2016, 4, 44.	2.1	9
15	The Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model. Pharmaceutics, 2021, 13, 205.	2.0	9
16	Control of Francisella tularensis Intracellular Growth by Pulmonary Epithelial Cells. PLoS ONE, 2015, 10, e0138565.	1.1	8
17	Assessment of stability of sulphated lactosyl archaeol archaeosomes for use as a vaccine adjuvant. Journal of Liposome Research, 2021, 31, 237-245.	1.5	8
18	Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model. Pharmaceutics, 2021, 13, 257.	2.0	7

#	Article	IF	Citations
19	Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines. Methods in Molecular Biology, 2022, 2412, 179-231.	0.4	7
20	Measurement of Antigen-Specific IgG Titers by Direct ELISA. Methods in Molecular Biology, 2021, 2183, 537-547.	0.4	6
21	A Method to Evaluate In Vivo CD8+ T Cell Cytotoxicity in a Murine Model. Methods in Molecular Biology, 2021, 2183, 549-558.	0.4	5
22	Effect of Chiral Purity on Adjuvanticity of Archaeol-Based Glycolipids. Journal of Medicinal Chemistry, 0, , .	2.9	2
23	Methods to Evaluate Immune Cell Recruitment and Cellular Uptake and Distribution of Antigen Following Intramuscular Administration of Vaccine to Mice. Methods in Molecular Biology, 2021, 2183, 513-524.	0.4	0